Updated: 23rd June 2026
Reviewed by: David Small, BSc (Hons), MSc, MTOPRA (Founder and CEO)
Why IVD Consultancy Has Become Essential Under the IVDR
The challenge isn’t just “more paperwork”. IVDR changes what good looks like: stronger performance evidence, tougher classification logic, and (for most IVDs) mandatory involvement with a Notified Body. That combination is exactly why specialised IVD consultancy has gone from “nice to have” to “this is how we keep our portfolio on the EU market”.
This article explains what an IVD consultant actually does, outlines proven IVDR compliance strategies, and helps you decide when external support is essential versus when you can sensibly keep it in-house.
New to the IVDR?
Effective regulatory strategies start with a strong understanding of the EU In Vitro Diagnostic Regulation. For a complete overview of IVDR classification, performance evaluation, technical documentation, CE marking, UDI, EUDAMED and compliance requirements, explore our Complete EU IVDR Guide.
What is IVD consultancy?
IVD consultancy is specialised regulatory, quality, and scientific support, focused specifically on in vitro diagnostic devices under Regulation (EU) 2017/746 (IVDR).
It’s different from general medical device consulting because IVDR has its own “physics”:
- A risk-based IVD classification system (Classes A–D) with different evidence and oversight expectations than MDR devices.
- Performance evaluation as a lifecycle activity, not a one-off “submit and forget” event (Annex XIII).
- Notified Body involvement for most IVDs (practically speaking: everything except certain Class A cases).
So what does an IVD consultant help with, in plain terms?
- IVDR gap assessments against Annex II (technical documentation), Annex III (PMS), and Annex XIII (performance evaluation).
- IVD classification and conformity route analysis (including borderline and “this will be reclassified in review” risks)
- Technical documentation structure, content, and traceability (claims → evidence → labelling → risk)
- Performance evaluation strategy and PER support (scientific validity, analytical performance, clinical performance)
- QMS alignment (typically ISO 13485-based) for IVDR PMS, vigilance, and ongoing updates
- Notified Body engagement: submission quality, Q&A cycles, nonconformity responses, change control
IVD consultancy becomes critical when:
- You’re transitioning legacy IVDD devices to IVDR
- You have Class C/D devices and can’t afford weak PERs or late rework
- Your in-house team is strong – but stretched thin across multiple jurisdictions and deadlines
Understand Your Article 10 IVDR Obligations
A successful IVDR implementation strategy begins with understanding your legal responsibilities as a manufacturer. Learn how Article 10 covers quality management systems, technical documentation, risk management, performance evaluation, post-market surveillance and ongoing regulatory compliance in our Guide to Article 10 of the EU IVDR.
Why IVDR compliance is so challenging
IVDR didn’t just tweak the rules. It changed the operating model.
Under Regulation (EU) 2017/746, classification is risk-based, performance evaluation is explicit and structured, and the system expects continuous evidence generation and post-market updates.
One big structural shock is oversight capacity. Under IVDR, Notified Bodies are involved in the conformity assessment for the majority of IVDs, because only limited categories can self-declare without NB involvement. That means:
- More manufacturers are competing for fewer review “slots”
- Review cycles tend to be longer
- The cost of getting it wrong is higher (because rework happens inside a queue)
That’s why IVDR compliance strategies matter. They’re not corporate jargon – they’re how you triage effort and reduce “surprise reclassification + missing evidence + NB bottleneck” pain.
External reference: The legal foundation is the IVDR itself: Regulation (EU) 2017/746.
Core IVDR compliance strategies for IVD manufacturers
Strategy 1: Start with a robust IVDR gap assessment
This is the least glamorous strategy, and also the one that prevents expensive chaos later.
A good IVDR gap assessment:
- Compares your current file set against Annex II (technical documentation), Annex III (PMS), and Annex XIII (performance evaluation).
- Flags classification changes and conformity route implications
- Identifies PER evidence gaps (and whether they’re “paper gaps” or “real data gaps”)
- Exposes QMS misalignment (especially PMS/vigilance interfaces and traceability)
Then it does the most important thing: it turns findings into a prioritised plan. Not everything has to be fixed at once, but the right things must be fixed first.
A practical prioritisation model that Patient Guard often uses in IVD consultancy:
- Risk class (C/D first)
- Revenue/patient impact (what must stay on market)
- Evidence gap size (quick wins vs “we need a study”)
- Notified Body dependency (when you must book capacity)
Found Gaps in Your Performance Evidence?
A robust IVDR gap assessment should examine the complete Performance Evaluation pathway, from scientific validity and analytical performance through to clinical performance, the PER and ongoing PMPF. Explore the full process in our Guide to IVDR Performance Evaluation.
Strategy 2: Confirm correct IVD classification early
Misclassification is one of the most common and costly IVDR mistakes because it cascades into:
- The wrong conformity route
- The wrong performance evidence plan
- The wrong Notified Body expectations
- And the wrong timeline assumptions
Classification is driven by intended purpose and impact on patient management and public health. IVDR classification guidance is refined and revised over time through MDCG outputs, so relying on “what we did under IVDD” is… optimistic.
A useful anchor for your team is the MDCG classification guidance ecosystem (and its revisions). MedTech Europe, for example, has tracked updates and revisions to MDCG 2020-16 related guidance.
Practical move: pressure-test classification with Notified Body expectations early. The goal is to avoid “We built a Class B file… and it’s actually Class C” during review.
Need Expert Support with IVDR Classification?
Correctly classifying an IVD is only the first step towards IVDR compliance. Our regulatory specialists can help determine the appropriate classification, develop your regulatory strategy, prepare Technical Documentation, Performance Evaluation Reports and support your route to CE marking. Learn more about our IVDR Consultancy Services.
Strategy 3: Strengthen performance evaluation
It’s important to treat it like a product, not a document. Under Annex XIII, performance evaluation has three pillars:
- Scientific validity
- Analytical performance
- Clinical performance
And importantly: this is lifecycle-based. A PER is not just a compilation exercise; it’s a structured argument that your intended purpose and performance claims are supported by evidence, and that post-market learning feeds back into the story.
Common gaps we see in legacy transitions:
- Clinical performance evidence is thin, outdated, or not aligned to intended use
- Performance claims exist in marketing or IFU language but aren’t supported by robust data
- Literature is used without a strong appraisal method or relevance justification
- The linkage between performance claims and risk controls is weak
Good IVD consultancy helps you rebuild the logic chain:
Intended purpose → performance claims → evidence plan → evidence appraisal → conclusions → PMS/PMPF updates
(If that chain breaks anywhere, Notified Bodies tend to notice. They’re quite good at noticing… they’re actually annoyingly good.)
Building Your IVDR Performance Evaluation?
A robust Performance Evaluation starts with establishing Scientific Validity for the IVD. Manufacturers need to identify, assess and document appropriate evidence supporting the association between the analyte and the relevant clinical condition or physiological state. See our practical IVDR Scientific Validity guidance for a detailed explanation of the requirements.
The role of an IVD consultant across the IVDR lifecycle
Think of a capable consultant as “regulatory systems engineering”: they connect quality, evidence, and submission strategy so your file behaves coherently in review.
Pre-submission and transition planning
A strong transition plan usually includes:
- Portfolio segmentation: transition vs redevelop vs withdraw
- Transitional provisions planning (and the reality that “extensions” don’t remove the need to do the work)
- Timelines aligned to NB capacity and likely review cycles
- A device-by-device evidence strategy (PER maturity is rarely uniform across a portfolio)
External reference: The European Commission’s medical devices regulations pages and implementation updates are the best “official pulse” for IVDR context and guidance signposting.
Still Using an IVDD Essential Requirements Checklist?
Transitioning from the IVDD to the IVDR means replacing the old Essential Requirements Checklist with an Annex I General Safety and Performance Requirements (GSPR) Checklist. Learn how to perform a gap analysis, update your technical documentation and build an audit-ready compliance checklist in our IVDD Essential Requirements vs IVDR GSPR Guide.
Technical documentation and QMS alignment
Here’s where many teams get stuck: they treat technical documentation as a “Regulatory deliverable” and QMS as a “Quality deliverable”.
IVDR expects these to be integrated:
- Risk management ↔ performance evaluation ↔ PMS
- Change control ↔ updates to claims, IFU, PER, and post-market plans
- Vigilance ↔ trending ↔ corrective action ↔ PER updates
Your ISO 13485 QMS can support this beautifully, but only if your procedures clearly define responsibilities, inputs/outputs, and update triggers.
Build a Quality Management System That Supports IVDR Compliance
A robust Quality Management System is essential for achieving and maintaining IVDR compliance. Discover how ISO 13485 helps manufacturers implement effective quality processes, document control, risk management, supplier oversight, internal audits and continual improvement throughout the device lifecycle.
Notified Body engagement
A consultant’s job here is not magic, but disciplined submission hygiene:
- Reducing avoidable questions by making files readable, traceable, and internally consistent
- Preparing structured responses to NB questions and nonconformities
- Keeping change control clean during review cycles
Preparing for an IVDR Notified Body Assessment?
Selecting the right Notified Body and preparing for conformity assessment are critical steps towards IVDR certification. Learn how Notified Bodies operate, how to choose the right certification partner, what documentation to prepare and how to avoid common causes of delays in our Complete Guide to Notified Bodies.
Post-market surveillance and vigilance
Under IVDR, PMS and PMPF aren’t side quests. They’re part of the lifecycle evidence engine.
An IVD consultant typically supports:
- PMS plans that actually match the device’s risk class and real-world use
- PMPF plans that close evidence gaps (not just “we will monitor complaints”)
- Vigilance reporting integration into the QMS
- Post-market data feeding PER updates (so the “lifecycle” claim is real)
Common IVDR pitfalls an IVD consultancy helps you avoid
Let’s name the usual suspects:
- Assuming IVDD evidence is “close enough”
- Underestimating the scale and structure of performance evaluation
- Engaging Notified Bodies too late (or without a strategy)
- Fragmented documentation: claims in one place, evidence in another, risk controls somewhere else entirely
- No clear lifecycle update triggers (so your PER quietly goes stale)
Structured consultancy reduces:
- Rework
- Review cycles
- Market disruption
- And the specific kind of team burnout that comes from answering the same NB question three times because the file still isn’t saying what you think it’s saying
Choosing the right IVD consultancy partner
Not all consultants are created equal. Some are excellent, whereas some are basically a Word template with a billing rate.
What to look for
- Demonstrated IVDR experience (not generic MDR with “we can do IVDs too”)
- Real performance evaluation expertise (scientific validity + analytical + clinical)
- Evidence of Notified Body interaction experience (and not just “we submitted once”)
- A structured methodology: scope, deliverables, timelines, responsibilities
- Clear approach to knowledge transfer (so you’re not dependent forever)
Red flags
- “Guaranteed fast certification” (no one controls NB timelines)
- Generic ISO-only approaches that ignore performance evaluation depth
- No IVD-specific case studies or examples
- Vague scope, vague deliverables, vague everything (except the invoice)
How Patient Guard supports IVDR compliance
Patient Guard operates as a specialist IVD consultancy designed for real-world IVDR constraints. Some of these include limited NB capacity, evidence gaps, and the need for sustainable post-market processes.
Typical support includes:
- IVDR gap assessments and transition roadmaps
- Performance evaluation (PER) strategy and documentation support
- Technical documentation build/repair with traceability mapping
- ISO 13485 + IVDR-aligned QMS implementation (especially PMS/vigilance integration)
- Ongoing post-market and regulatory support as devices evolve
This is meant to be a long-term compliance system, not a one-off “panic sprint” before an audit.
If your PER and PMS don’t clearly “talk” to each other yet, that’s a good moment to bring in an IVD consultant before it becomes a Notified Body comment.
IVDR compliance timelines and what to do next
IVDR timelines and transitional provisions can create a false sense of safety. Extensions can protect market continuity in theory, but they don’t solve:
- Evidence gaps
- NB capacity constraints
- The time it takes to generate performance data properly
- The time it takes to rebuild a QMS interface around PMS and performance evaluation
So your decision framework is brutally simple:
- Do nothing → high regulatory and commercial risk
- Partial internal effort → moderate risk (often with hidden bottlenecks)
- Structured IVDR compliance strategies with IVD consultancy → controlled, manageable risk
External reference: Keep an eye on the European Commission’s medical devices regulations hub for implementation updates and guidance signposting.
Preparing for the 2026 IVDR Transitional Deadlines?
A successful IVDR strategy starts with understanding the amended transitional provisions and the critical milestone dates that determine eligibility for the extended transition periods. Learn about the Class C application deadline, written agreement requirements, ongoing compliance obligations and practical planning strategies in our Guide to the 2026 IVDR Transitional Provisions.
Conclusion
IVDR compliance is not a one-off regulatory event; it’s a lifecycle commitment. The manufacturers who succeed are the ones who treat performance evaluation, PMS, and QMS integration as a living system, not a pile of documents.
A specialist IVD consultancy helps you do three things well:
- Build a credible evidence story (PER done properly)
- Make your documentation traceable and review-friendly
- Keep compliance sustainable after certification, through post-market reality
Contact Patient Guard to develop tailored IVDR compliance strategies for your IVD portfolio.
Frequently Asked Questions About IVD Consultancy
An IVD consultancy supports IVDR classification, gap assessments, technical documentation, performance evaluation (PER), QMS alignment (often ISO 13485-based), and Notified Body engagement across the device lifecycle.
Engage early if you’re transitioning legacy IVDD devices, have Class C/D IVDs, face performance evidence gaps, or need a realistic plan around Notified Body timelines.
It depends on risk class, evidence maturity, and NB availability. The “real time” is usually driven by performance evidence generation and review cycles, not just document writing.
Challenges are usually weak clinical performance evidence, outdated or unstructured scientific validity rationale, and poor traceability between claims, evidence, and post-market plans.
IVDR is performance-evaluation centric (Annex XIII) and classification-driven (A–D) in a way that’s materially different from MDR clinical evaluation structures.
Yes. Patient Guard provides end-to-end IVD consultancy, including transition planning, PER and technical documentation support, QMS alignment, and Notified Body interaction support.
References
This guide is based on the following legislation, international standards and official regulatory guidance relating to IVDR compliance, regulatory strategy and Quality Management Systems for in vitro diagnostic medical devices.
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR) | Provides the legal framework governing classification, conformity assessment, Performance Evaluation, Technical Documentation and post-market obligations for in vitro diagnostic medical devices. |
| European Commission | MDCG Endorsed Documents and Other Guidance | Provides official Medical Device Coordination Group (MDCG) guidance supporting IVDR implementation, including classification, Performance Evaluation, Technical Documentation and conformity assessment. |
| European Commission | Notified Bodies for Medical Devices | Provides official information on the designation and responsibilities of Notified Bodies responsible for IVDR conformity assessment and certification. |
| International Organization for Standardization (ISO) | ISO 13485:2016 – Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes | Defines the internationally recognised Quality Management System requirements expected of manufacturers implementing and maintaining IVDR-compliant quality systems. |
| International Organization for Standardization (ISO) | ISO 14971:2019 – Medical Devices – Application of Risk Management to Medical Devices | Provides the internationally recognised framework for identifying, evaluating and controlling risks throughout the lifecycle of in vitro diagnostic medical devices. |
| European Commission | EUDAMED – European Database on Medical Devices | Provides official information on EUDAMED, supporting actor registration, UDI/device registration, certificates and market surveillance under the IVDR. |
IVDR legislation, regulatory guidance and conformity assessment requirements continue to evolve. Manufacturers should always consult the latest published legislation, recognised standards and official guidance when developing, certifying and maintaining compliant in vitro diagnostic medical devices.
Patient Guards Recent Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
Patient Guards Related Services
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
